However, most clinically evaluated GRPR-targeted radiopharmaceuticals derived from BBN showed extremely high pancreas uptake, which not only limits the detection of GRPR-expressing tumor lesions in and near the pancreas but also lowers the maximum tolerated dose for radiotherapeutic applications [9,10,11,12,13,14,17]. Here, GRPR is linked to neoplasm.